Joon Ho Moon

ORCID: 0000-0003-3756-796X · 1 paper in corpus

article 2023

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

·doi:10.1016/s0140-6736(22)02036-0

BackgroundJanus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK…